Parenteral – PareSol™ Technology Overview

The development of injectable formulations is especially challenging for insoluble API. Standard methods rely on solubilizing agents to achieve a shelf-stable formulation. Unfortunately, upon administration, many of these formulations rapidly precipitate at the site of injection leading to poor performance and potential safety concerns.

PareSol™ is a rapid formulation assessment technology that not only screens API with acceptable excipients for injectable use, but also addresses the need to avoid rapid precipitation upon administration. PareSol™ combines API physicochemical property analyses, in silico physiological-based modeling, and in vitro performance measurement screening to optimally select preferred formulations.

PareSol™ is designed to work with minimal bulk requirements and timelines. Typically, as little as 200 mg per compound and 2-3 weeks is required to obtain a prototype formulation.